Navigation Links
Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
Date:10/21/2010

ng statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.____________________________(1) Rossignol JF. Thiazolides: A new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009;5:667-674.(2) Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide, and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antivir Res. 2008;77:56-63.(3) Korba BE, Elazar M, Lui P, et al. Studies of the potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008;52:4069-4071.(4) Yon C, Viswanathan P, Rossignol JF, Korba BE. Resistance to nitazoxanide is associated with alterations in the host and not the virus in HCV replicon-containing cultures. Submitted for publication.(5) Korba BE, Elazar M, Liu P, et al. Potential role for nitazoxanide in combination with STAT-C agents for the inhibition of HCV replication without the development of resistance. Hepatology. 2008;48(suppl):356A.(6) Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2008;28:574-580.(7) Rossignol JF, Elfert A, El-Gohary Y, et al. Improved virologic response in patients with chronic hepatitis C genotype 4 treated with nitazoxanide plus peginterferon alfa-2a with or with
'/>"/>
SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
2. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
3. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
4. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
8. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
9. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
10. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
11. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014 Children,s National Health ... Sept. 29 at 5 p.m. EDT for its ... in response to continued strong interest from inventors.  ... will be awarded to the winning presentations at ... Symposium hosted by Children,s National in October. For ...
(Date:9/22/2014)... 22, 2014 Persistence Market Research ... Market Study on Ophthalmic Devices: Asia ... devices market was valued at USD 29,171.5 million in 2014 ... 6.5% from 2014 to 2020, to reach an estimated ... Browse the full Global Market Study on Ophthalmic Devices:  ...
(Date:9/22/2014)... , Sept. 22, 2014 /CNW/ - T-Bird Pharma ... focused on developing premium quality medical marijuana products, is ... Biomedical Inc. ("Thunderbird"), has signed a definitive lease agreement ... , BC.  The facility has 28,966 square feet ... 14,500 square feet of mezzanine space for a total ...
Breaking Medicine Technology:Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 2T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 3
... CPF Calls on Manufacturer and FDA to Expedite Review of ... The Coalition for Pulmonary Fibrosis (CPF) is calling this a ... a pivotal Phase III clinical trial is completed for Pirfenidone ... way for the first FDA-approved therapy to treat PF - ...
... Intellectual property based on breakthrough research from a ... Montreal Heart Institute Research Centre, Canada.TOULOUSE, France and ... SA (Cerenis), a privately held pharmaceutical company developing ... metabolic diseases, today announced that it has in-licensed ...
Cached Medicine Technology:Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis 2Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis 3Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis 2
(Date:9/22/2014)... whole eye transplant seems futuristic, if not impossible. ... Department of Defense, researchers at University of California, ... make implantation of an entire, functional eye a ... a holy grail for vision restoration," said Jeffrey ... co-recipient with colleagues at University of Pittsburg Medical ...
(Date:9/22/2014)... PA (PRWEB) September 22, 2014 An ... for patients to the problem of side-sleeping. "My lower ... side, so I designed a solution to this problem," ... asleep comfortably than to have your arm 'fall asleep.'" ... on his or her side more comfortably. It avoids ...
(Date:9/22/2014)... West Orange, NJ. September 22, 2014. Kessler researchers ... of a 10-week psychoeducational wellness program in people ... in mood, overall mental health, perceived stress, and ... wellness group for individuals living with MS: Description ... September 3 in the International Journal of ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Scans ... they learn to read. This finding could potentially ... other reading difficulties early on, preliminary research suggests. ... in children with dyslexia as well as most ... Hoeft, an associate professor of child and adolescent ...
(Date:9/22/2014)... 2014 Pain does not need to rule ... user- and reader-friendly book designed to guide the individual who ... This inspirational book is written to help the reader who ... way to regain a pain-free life — a daily “go-to” ... , Chronic pain has become an epidemic, with over 100 ...
Breaking Medicine News(10 mins):Health News:Looking ahead: Whole eye transplant under development 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Naturopathic Doctor Inspires and Guides Those Who Suffer with Chronic Pain, Pointing the Way Back to Pain-free Living 2
... Francisco's 2002 Gay Pride, San Francisco Department of Public Health ... ,In the above said campaign, a cartoon penis by ... hundreds of homo whores who had gathered there to get ... were not happy with the Ad and scoffed at the ...
... habits, is easily acquired but quite difficult to stop.// All ... or at least have to try out recommended smoking cessation ... the ages of 16 and 24 years do try to ... try out tested methods. ,An article presented in ...
... A US company claimed to have developed a weight reduction ... also could cut the risk of heart disease, diabetes and ... five to 10 percent when taken for a year. ... developed by Californian biopharmaceutical firm Orexigen for 48 weeks lost ...
... apple and plum, now strawberry wine will add variety from ... the Horticulture Produce Marketing Corp's (HPMC) juice and wine processing ... ,The new wine was produced after year-long research by experts ... town Kalpa in Kinnaur district, which produces some of the ...
... Systemic sclerosis (SSc) is a chronic autoimmune disorder ... tissue fibrosis.// More than skin deep, this thickening ... capillaries, the gastrointestinal tract, the lungs, and the ... organ dysfunction, serious illness, and death. Researchers have ...
... better safety for patients in ICU by adhering to ... threatening// catheter-related infections. ICUs can become thoroughly aseptic by ... syringes and catheters. A detailed report was made by ... of the report are published in New England Journal ...
Cached Medicine News:Health News:Tried To Quit Smoking And Failed? Call 1-800-QUIT-NOW 2Health News:New Treatment Offers Hope for Systemic Sclerosis 2Health News:Simple Steps to Safe Guard Patients from Bloodstream Infections in ICU 2
... and high power negative lens delivering magnification ... benefit of this system is ease of ... made possible due to a superior depth ... and individual interpupillary adjustment provides stability for ...
... represents a breakthrough for patients experiencing degenerative ... system gathers bone during decompression, bone bed ... into the implant's chamber produces a local ... the iliac crest. The BAK/C implant is ...
Inside and out, the Achieva is designed to unleash a new era, in which the clinical capabilities of MR will further expand....
Signa Profile is built on the Signa foundation to deliver speed & image quality....
Medicine Products: